SCHEDULE: Gary Shirinyan Reports 7.7% Stake in Aspire Biopharma

Gary Shirinyan has filed a Schedule 13G, reporting beneficial ownership of 99,900 shares, representing 7.7% of Aspire Biopharma Holdings, Inc. common stock.

Summary

• Gary Shirinyan has reported beneficial ownership of 99,900 shares of Aspire Biopharma Holdings, Inc. common stock.
• This holding represents 7.7% of the class of securities.
• The filing is a Schedule 13G, indicating that Shirinyan is a passive investor.
• The date of the event requiring this filing was June 17, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• Gary Shirinyan has acquired a significant stake (7.7%) in Aspire Biopharma Holdings, Inc., potentially indicating confidence in the company's future.
• The filing is a Schedule 13G, suggesting a passive investment approach rather than an attempt to control the company.

Negatives

• The filing does not provide any new operational or financial performance data for Aspire Biopharma Holdings, Inc.
• The filing is a routine disclosure and does not offer insights into the company's strategic direction or growth prospects.

Risks

• The filing does not explicitly mention any risks associated with the company or the investment.
• As a passive investment, the risk profile is tied to the overall performance and market perception of Aspire Biopharma Holdings, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders who acquire more than 5% of a company's stock. This filing indicates Gary Shirinyan's passive investment in Aspire Biopharma Holdings, Inc., a biotechnology company, without suggesting any immediate strategic shift or activist intent.

Stakeholder Impact

• Shareholders: The acquisition of a 7.7% stake by a new significant holder may be viewed positively, suggesting increased investor interest, but without further context, the impact is neutral.
• Management: The filing indicates a passive investment, so no immediate impact on management's strategic decisions is expected.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Gary Shirinyan will continue to hold the reported shares.
• Further filings may be required if Shirinyan's beneficial ownership changes significantly.

Key Dates

Keywords

Aspire Biopharma Holdings, Gary Shirinyan, Schedule 13G, Beneficial Ownership, Common Stock, Investment